SPY458.97-10.47 -2.23%
DIA349.02-9.01 -2.52%
IXIC15,491.66-353.57 -2.23%

ANI Pharmaceuticals Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of Novitium Pharma

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to

Benzinga · 11/11/2021 06:54

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma. The divestitures required by the FTC of development rights to one generic drug and assets with respect to another generic drug are immaterial to the Company's business.

The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained for the acquisition of Novitium Pharma by ANI. The closing of the acquisition remains subject to other customary closing conditions set forth in the purchase agreement. ANI currently expects that the acquisition will be completed on or about November 18, 2021.